Naveen Pemmaraju/mdanderson.org
May 18, 2025, 12:23
Naveen Pemmaraju: The Evolving Landscape of Epigenetic Target Molecules and Therapies in Myeloid Cancers
Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center, shared a post on X about a paper he co-authuored with colleagues published in Leukemia:
“Delighted to share our brand new review article led by Florian Heidel. The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on AML and MPN.”
Title: The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms
Authors: Michael Kühn, Naveen Pemmaraju, Florian Heidel.
You can read the Full Article in Leukemia.
More posts featuring Naveen Pemmaraju.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 2, 2025, 16:54
Sep 2, 2025, 16:41
Sep 2, 2025, 16:27
Sep 2, 2025, 16:24
Sep 2, 2025, 16:18
Sep 2, 2025, 15:56